NDTV | Gilead announces Phase II results in hepatitis C trials Vaccine News Daily Gilead scientists evaluated the treatment regimen of an investigational once-daily nucleotide analogue of sofosbuvir plus ribavirin for the prevention and treatment of chronic hepatitis C virus infection among patients undergoing liver transplantation. Research tackles liver transplant failure New HCV Drugs Offer Hope After Transplant |
